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Abstract
 
The COOH-terminal peptides of pigeon and moth cytochrome c, bound to mouse IE
 
k
 
, are
two of the most thoroughly studied T cell antigens. We have solved the crystal structures of the
moth peptide and a weak agonist–antagonist variant of the pigeon peptide bound to IE
 
k
 
. The
moth peptide and all other peptides whose structures have been solved bound to IE
 
k
 
, have a
lysine filling the p9 pocket of IE
 
k
 
. However, the pigeon peptide has an alanine at p9 shifting
the lysine to p10. Rather than kinking to place the lysine in the anchor pocket, the pigeon
peptide takes the extended course through the binding groove, which is characteristic of all
other peptides bound to major histocompatibility complex (MHC) class II. Thus, unlike MHC
class I, in which peptides often kink to place optimally anchoring side chains, MHC class II im-
poses an extended peptide conformation even at the cost of a highly conserved anchor residue.
The substitution of Ser for Thr at p8 in the variant pigeon peptide induces no detectable sur-
face change other than the loss of the side chain methyl group, despite the dramatic change in
recognition by T cells. Finally, these structures can be used to interpret the many published
mutational studies of these ligands and the T cell receptors that recognize them.
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Introduction
 
One of the most heavily studied antigenic peptides in mice
comes from the COOH-terminal end of pigeon cyto-
chrome c (PCC),
 
*
 
 encompassing amino acids 89–103
(peptide derived from the COOH terminus of PCC
[pPCC]). This peptide contains the dominant pigeon cy-
 
tochrome c epitope for CD4
 
 
 
 T cells in many strains of
mice (1). Over the years, many immunological principles
have been defined and studied using this peptide and its
homologues from the cytochrome c’s of other species, es-
pecially the equivalent peptide from moth cytochrome c
(pMCC).
In H-2
 
k
 
 or H-2
 
a
 
 mice, the IE
 
k
 
 MHC class II molecule
(MHCII) presents pPCC and pMCC to T cells. The phe-
nomenology associated with the response to these peptides
led to the discovery of two complementing “immune re-
sponse” genes that later turned out to be the structural
genes for the 
 
 
 
 and 
 
 
 
 chains of the IE
 
k
 
 molecule (2). Muta-
tional studies have predicted which of the pPCC and
pMCC amino acid side chains are important for the bind-
ing of the peptides to the IE
 
k
 
 molecule (3, 4). An important
difference between pMCC and pPCC is the fact that
pPCC has an Ala inserted at amino acid 103. This insertion
causes pPCC to raise a “heteroclitic” response to the
pMCC, which means that although pPCC and pMCC are
virtually completely cross reactive, essentially all T cell
clones raised by immunization with pPCC respond better
to pMCC (5). The data have suggested that this phenome-
non is linked to the interaction of the peptide with the
MHC molecule rather than the 
 
  
 
TCR, but the structural
basis of this difference has remained unknown (6).
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*
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c-terminus of moth cytochrome c; PCC, pigeon cytochrome c; pPCC,
peptide derived from the COOH terminus of pigeon cytochrome c. 
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The repertoire of 
 
  
 
TCR expressed by T cells respond-
ing to pPCC and pMCC is dominated by receptors bear-
ing AV11S1 and AV11S2 (V
 
 
 
11.1 and V
 
 
 
11.2, respec-
tively) and BV3S1 (V
 
 
 
3) (7). Many V
 
 
 
11/V
 
 
 
3
 
 
 
 T cell
clones/hybridomas specific for these peptides are in wide-
spread use (8–10) and the genes for the 
 
  
 
TCRs of a
number of these clones have been used to produce
 
  
 
TCR-transgenic mice (11–14). These mice, as well as
those transgenic for various versions of the IE
 
k
 
 molecule
(15, 16), have been used over the years to study the princi-
ples of T cell activation as well as positive and negative se-
lection in the thymus. The interaction of 
 
  
 
TCRs with
IE
 
k
 
/pPCC or IE
 
k
 
/pMCC has been extensively studied
both in vitro and in vivo. These studies have predicted
which of the 
 
  
 
TCR, IE
 
k
 
, and peptide amino acids are
important in the interaction (4, 6, 17–21).
pPCC and pMCC have also been used to study the phe-
nomenon of antagonism. Amino acid variants of a number
of antigenic peptides have been identified, which not only
fail to stimulate particular T cell clones or hybridomas that
had been raised to the wild-type peptide, but also render
the T cell unresponsive to a subsequent or simultaneous
challenge with the wild-type peptide (22). Although the
mechanism of this phenomenon is not fully understood, it
has been shown to involve some type of aberrant or in-
complete receptor signaling that effectively desensitizes the
receptor to subsequent ligation. In the case of pPCC and
pMCC, several clones were antagonized by variant pep-
tides bearing only slight differences from the wild-type
peptides (23, 24)
In the current study, we have solved the crystal structure
of the IE
 
k
 
 molecule in complex with either pMCC or
pPCC bearing a single amino acid change (Thr to Ser at
amino acid 102) that renders it either a poor agonist or an
antagonist for many T cell clones. The structures reveal the
basis for the differences between pMCC and pPCC in
binding to IE
 
k
 
. They also show that the Thr to Ser change
results in only a very minor surface difference between the
two molecules. Finally, the structures support many of the
predictions made in previous studies concerning contacts
between the peptides and either the IE
 
k
 
 molecule or the T
cell receptor.
 
Materials and Methods
 
IE
 
k
 
–pMCC and IE
 
k
 
–pPCC(T102S).
 
The expression, pro-
duction, and purification of soluble IE
 
k
 
 with covalently attached
peptides have been previously described (25–27). In this study
two different peptides were used: pMCC, RDLIAYLKQATK,
corresponding to amino acids 92–103 of moth cytochrome c, and
pPCC(T102S), RDLIAYLKQASAK, corresponding to amino
acids 92–104 of pigeon cytochrome c, with the exception that
the Thr at amino acid 102 was changed to Ser. In discussing the
structure of individual peptide amino acids when bound to IE
 
k
 
,
we use the convention of designating the first peptide anchor
amino acid as p1 and number the other amino acids accordingly,
e.g., p9Lys or p9K. IE
 
k
 
 amino acids are designated by chain and
number, e.g., 
 
 
 
9Glu or 
 
 
 
66Asp. Also, for simplicity, MHCII co-
valent peptide complexes are referred to with a (–) connecting
 
the MHC and peptide name, e.g., IE
 
k
 
–pMCC, whereas nonco-
valent complexes use a (/), e.g., IE
 
k
 
/pMCC.
 
Crystallization.
 
Both IE
 
k
 
–pMCC and IE
 
k
 
–pPCC(T102S)
were crystallized by the hanging drop method. IE
 
k
 
–pMCC crys-
tals were grown in 1-
 
 
 
l drops containing 
 
 
 
11 mg/ml of protein,
12% PEG-4000, 12% 2-propanol, and 60 mM of sodium acetate
buffer at pH 5.5. IE
 
k
 
–pPCC(T102S) crystals were grown in 1-
 
 
 
l
drops containing 
 
 
 
10 mg/ml of protein, 14% PEG-4000, 14%
2-propanol, 1.4% ethylene glycol, 70 mM of sodium acetate
buffer at pH 5.0, and 320 mM of ammonium sulfate.
 
Data Collection.
 
IE
 
k
 
–pMCC and IE
 
k
 
–pPCC(T102S) crystals
were cryopreserved by briefly soaking in mother liquor with the
addition of 20% ethylene glycol and 10% glycerol followed by
rapid cooling in a gaseous stream of nitrogen at 100
 
 
 
K (Oxford
Cryosystems). Diffraction data for a single IE
 
k
 
–pMCC crystal
were collected in the X4A beamline at the National Synchrotron
Light Source at Brookhaven National Laboratory using a wave-
length of 0.9795 Å and PhosphorImager plates with 2
 
 
 
 oscilla-
tions. Data were processed with Denzo and scaled/merged with
SCALEPACK (HKL Research, Inc.; reference 28). Diffraction
data for a single IE
 
k
 
–pPCC(T102S) crystal were collected in the
crystallography facility at the Howard Hughes Medical Institute
using a wavelength of 1.54 Å, a Rigaku rotating anode generator,
Yale mirrors, and a RAXIS IV detector with 1
 
 
 
 oscillations. Data
were processed, scaled, and merged using the BIOTEX program
(Molecular Structure Corp.). Both of the crystals were of space
group C2 with similar dimensions and packing, and both had two
molecules in the asymmetric unit. Details of the collection and
processing statistics are in Table I.
 
Structure Determination.
 
The structures of IE
 
k
 
–pMCC and
IE
 
k
 
–pPCC(T102S) were solved by molecular replacement using
the program AMoRe (29, 30). The search model was the IE
 
k
 
–
pHB structure with the peptide and linker removed (31). The
very low resolution data (
 
 
 
10 Å) from the IE
 
k
 
–pPCC(T102S)
dataset were omitted due to problems with saturation. The initial
models were improved with rigid body refinement using the pro-
gram Xplor/CNS (32). Multiple rounds of refinement with
Xplor/CNS and model building with oxygen (33) were used to
improve the model when the peptides were added. The final
model of IE
 
k
 
–pMCC had 792 amino acids and that of IE
 
k
 
–
pPCC(T102S) had 794 amino acids. As in the case of the other
IE
 
k
 
 structures that we have solved, relatively weak electron den-
sity was seen for most of the linker attaching the peptide to the 
 
 
 
chain NH
 
2
 
 terminus, and for the loop connecting the first and
second 
 
 
 
 strands of the 
 
 
 
2 domain. In the later stages of refine-
ment, the following 
 
N
 
-acetyl glucosamines were added to some
asparagines based on positive electron density in Fo-Fc maps: six
to the IE
 
k
 
–pMCC structure and four to the IE
 
k
 
–pPCC(T102s)
structure. In addition, the following water molecules were
added: 215 to the IE
 
k
 
–pMCC structure and 317 to the IE
 
k
 
–
pPCC(T102s) structure. Refinement and final model statistics are
listed in Table I. For figures, average structures were calculated
for both molecules from the two molecules in the asymmetric
units using the programs MOLEMAN and AVEPDB (34, 35).
Coordinates have been submitted to the Protein Data Bank
(available at http://www.rcsb.org/pdb/ under accession numbers
1KT2 and 1KTD).
 
Results and Discussion
 
The Peptide Motif for Binding to IE
 
k
 
.
 
In previous studies
(31, 36), we reported that the structure of the IE
 
k
 
 molecule 
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bound to two different peptides: pHB, a highly immuno-
genic peptide derived from an allele of the 
 
 
 
 chain of
mouse hemoglobin and pHSP, a peptide derived from
HSP70, which is a major self-peptide that occupies natural
IE
 
k
 
. These structures revealed four anchor residues in each
peptide interacting with four pockets in the IE
 
k
 
 peptide
binding groove (Fig. 1 A). The very hydrophobic p1
pocket accepted amino acids with aliphatic side chains (Ile
in pHB and Val in pHSP). The large, somewhat hydropho-
bic p4 pocket was filled with a Phe in both cases. The very
hydrophilic p6 pocket contained a Glu in the case of pHB.
The carboxylate of this amino acid participated in an ex-
 
tensive hydrogen bonding network that included two IE
 
k
 
acidic amino acids (
 
 
 
11Glu and 
 
 
 
66Asp). In the case of
pHSP, the Ala at this position only filled the very top of the
pocket, with an extra water molecule now maintaining the
hydrogen bonding network. Finally, the p9 pocket of IE
 
k
 
consisted of a long tunnel culminating in a negatively
charged 
 
 
 
9Glu that formed a salt bridge with the 
 
 
 
 amino
group of a p9Lys at that position in both peptides.
This structural information, as well as other published
data (1, 4, 37–45), were used to align and predict the an-
chor residues of pMCC and pPCC(T102S), as well as
other peptides that are the dominant IE
 
k
 
 epitopes in for-
 
Table I.
 
Data Collection and Refinement Statistics
 
Data collection pMCC pPCC(T102S)
Space group C2 C2
Unit cell dimensions (Å) a 
 
 
 
 147.8, b 
 
 
 
 56.9, c 
 
 
 
 116.0 a 
 
 
 
 145.5, b 
 
 
 
 57.3, c 
 
 
 
 116.6
Unit cell angles (
 
 
 
)
 
 
 
 
 
 
 
 92.1
 
 
 
 
 
 
 
 94.2
No. of molecules in AU 2 2
Resolution limits (Å) 20-2.8 (2.95-2.80)a 100-2.4 (2.56-2.40)
Unique reflections 22,827 (3,185) 36,433 (5,970)
Completeness (%) 95.2 (93.4) 95.2 (90.2)
Averave redundancy 2.5 3.1
Average I/  11.1 (2.4) 16.8 (2.8)
Rmerge (%)b 9.7 (31.7) 4.7 (26.4)
Refinement
Resolution (Å) 20-2.8 (2.89-2.80) 10-2.4 (2.5-2.4)
Rejection criterion F   0F     0
Total reflections 22,378 (1,845) 35,965 (3,773)
Reflections used for Rfree 1,088 (85) 1,785 (191)
Rworkingc (%) 22.1 (32.2) 22.0 (31.3)
Rfreec (%) 29.3 (42.2) 27.9 (36.4)
Average B factors (Å2) 47.9 48.8
Ramachandran data
Percentage of residues in:
Favored regions 85.7 88.0
Allowed regions 13.3 10.9
Generously allowed regions 0.8 0.9
Disallowed regions 0.3 0.1
Rmsd
Bonds (Å) 0.0069 0.0064
Angles ( ) 1.397 1.288
Bfactor main chain (1.5)e (Å2) 1.95 1.31
Bfactor side chain (2.0)e (Å2) 1.45 1.39
Cross-validated coord. error (Å) 0.47 0.41
aAll data (outer shell).
bRmerge    (|I   I  )/ (I).
cRworking/free    ||Fo|   |Fc||/ |Fo|.
dExcluding Gly and Pro.
eTarget value.1046 Structures of Cytochrome c Peptides Bound to IEk
eign protein antigens, or major self-peptides isolated from
IEk naturally present on the surface of B cells, and thymic
epithelium in unimmunized mice (Fig. 2). This alignment
predicts an aliphatic amino acid at the p1 position. The p4
pocket is predicted to be more forgiving, preferring hy-
drophobic amino acids such as Phe and Leu, but also al-
lowing other amino acids. The p6 pocket appears to have a
preference for amino acids that can participate in the hy-
drogen bonding network underlying the peptide (Glu,
Gln, and Asn), but small side chains such as the Ala in
pHSP are also allowed. The p9 pocket is predicted almost
invariably to be Lys.
Using this alignment, the p1, p4, and p6 pockets of IEk
were predicted to contain Ile, Leu, and Gln, respectively, for
both pMCC and pPCC(T102S). Although the p9 amino
acid was predicted to be Lys for pMCC, two possibilities ex-
isted for pPCC(T102S). pPCC(T102S) has an Ala insertion
at p9 that shifts the Lys to p10. Therefore, either the Ala
must now occupy the p9 pocket or the peptide backbone
must kink to allow the shifted Lys side chain to remain in
the p9 pocket. In either case, the adjustments to the Ala in-
sertion might contribute to poorer binding by pPCC to IEk.
Interactions of pMCC and pPCCT102S with IEk.  To
test these predictions, we solved the crystal structures of IEk
bound to pMCC and pPCC(T102S) by molecular replace-
ment to resolutions of 2.8 and 2.4 Å, respectively, using the
high resolution IEk–pHB structure with the peptide re-
moved as a search model. In the final models, the back-
bones of the IEk portions of the structures were virtually
identical to that of the IEk in the IEk–pHB structure. For
example, using the program Swiss PDBViewer (46) to
compare the combined  1/ 1 domains, the RMSD’s
were 0.28 Å for backbone atoms and 0.54 Å for all atoms
comparing IEk–pMCC to IEk–pHB. Comparing IEk–
pPCC(T102S) to IEk–pHB, the values were 0.32 and 0.51
Å, respectively. Peptide omit electron density maps clearly
showed the peptides in the binding groove (Fig. 1, B and
C) and in the final models, the paths of the peptides
through the binding grooves were nearly identical to those
seen with IEk–pHB and IEk–pHSP (Fig. 1 D).
Figure 1. Structure of pMCC and pPCC(T102S) bound to IEk. (A) Solvent-accessible surface (probe radius of 1.4 Å) representation of the four pep-
tide amino acid binding pockets (p1, p4, p6, and p9) of IEk with the side chains of four bound peptides are shown. IEk surface colored by relative hydro-
phobicity (Gilliard scale). Gray, hydrophobic; white, neutral; green, hydrophilic. Peptide side chains are shown as wire frame. Yellow, carbon; blue, ni-
trogen; red, oxygen; cyan, water. The figure was made with Protein Explorer (http://proteinexplorer.org). (B) Peptide/water omit electron density map
(Fo-Fc, 2.5 ) surrounding pMCC from p1 to p11. The figure was made with the Swiss PDBViewer. (C) This shows the same as panel B for
pPCC(T102S), and also shows the electron density for an extra water molecule (W) in the p9 pocket. (D) Overlay of four peptides from IEk structures.
Cyan, pMCC; magenta, pPCC(T102S); green, pHSP; red, pHB. The structures were superimposed via the backbones of the  1 and  1 domains using
Swiss PDBViewer. The figure was made with the Swiss PDB Viewer.1047 Fremont et al.
The structure of pMCC bound to IEk confirmed the
MHCII binding motif prediction (Fig. 1, A, B, and D).
Side chains from four amino acids, Ile at p1, Leu at p4, Gln
at p6, and Lys at p9, filled the four IEk pockets. Amino ac-
ids at positions p1, p6, and p9, but not at p4, were pre-
dicted by mutagenesis experiments to be important in the
interaction of pMCC with IEk (4). In these experiments
virtually any amino acid could be substituted at the p4 po-
sition without penalty. These results suggest great flexibility
in this large pocket in accepting amino acid side chains and
relatively little contribution from the side chain to the
overall energy of pMCC binding.
As expected, the pPCC(T102S) peptide bound to IEk
(Fig. 1, A, C, and D) also has the Ile at p1, Leu at p4, and
Gln at p6, all in conformations very similar to those in
pMCC. The structure also clearly shows the adjustment to
the inserted Ala at the p9 position of the peptide. Although
the side chain of the Lys at p9 of pMCC points down
into the pocket, this position is occupied by the inserted
Ala whose methyl side chain only fills the very top of the
pocket, whereas the p10 Lys is shifted and rotated so that
the side chain is now completely solvent-exposed. An extra
water molecule is now found in the p9 pocket. This sug-
gests that the loss of the buried Lys side chain is most likely
a major reason for the weaker binding of pPCC compared
with pMCC.
Details of the peptide interactions with IEk in the region
of the p6 and p9 pockets are shown in Fig. 3. The side
chain of the p9Lys of pMCC extends through a hydro-
phobic tunnel to a salt bridge with  9Glu and interacts
with a water molecule (W2). Other interactions at this end
of the peptide include the highly conserved hydrogen
bonds between  61Trp and  69Asn, the peptide back-
bone seen in nearly all MHCII structures, and an extensive
hydrogen bond network that includes p6Gln,  66Glu,
 30Tyr, and several water molecules. In the IEk–pPCC
(T102S) structure, the interactions at p9 are lost and the
pocket is partially filled with an extra water molecule
(W4). However, the other details of the hydrogen bond-
ing network are preserved.
The main chain of pPCC(T102S) has not kinked to
maintain a Lys in the p9 pocket, but rather its path through
the binding groove is identical to that of pMCC. Kinks in
peptides bound to MHC class I (MHCI) are common (47,
48) and function to maintain the conserved binding of
MHCI to the peptide NH2 and COOH termini, and allow
the insertion of favorable amino acid side chains in the
MHCI binding pockets. However, in all solved structures
of MHCII, including those presented here, the peptide
takes a very similar, nearly linear course through the bind-
ing groove, held in place by hydrogen bonding between its
backbone and the side chains of conserved amino acids on
the MHC   helices (31, 49–53).
It is difficult to predict the net changes in the IEk–
pPCC(T102S) structure if the peptide were to be kinked
and rotated to preserve a Lys in the p9 pocket. The van der
Waals interactions with the Lys side chain as well as the salt
bridge and the hydrogen bonds to its  -amino group,
would be gained. However, it is likely that the conserved
peptide backbone interactions with  61Trp and  69Asn
would be lost. Also, depending on the precise nature of the
kink, the hydrogen bonding network involving the p6Gln
might be disturbed. Apparently, the energy gained by the
new interactions would not compensate for the loss of
these other interactions.
Peptide Amino Acids Interacting with   TCRs. The in-
teraction of IEk/pMCC and IEk/pPCC with the   TCRs
of many different T cell clones has been extensively stud-
ied. Various mutagenesis experiments have shown that the
amino acids at p2, p3, p5, p7, and p8 are involved in recog-
Figure 2. Peptide motif for
binding to IEk. The core se-
quences of pHB and pHSP are
aligned based on their solved
structures bound to IEk, with the
positions of the four anchor resi-
dues (p1, p4, p6, and p9) high-
lighted. A series of other IEk
binding peptides that were either
identified as the major epitopes
from foreign antigens or self-
peptides isolated from IEk, were
aligned based on the predicted
occupancy of the four binding
pockets with particular weight
on p1 and p9. Only the central
regions of the peptides are
shown. Abbreviations and refer-
ences: HB, mouse hemoglobin (37); HSP, mouse heat shock protein 70,
(38); MCC, moth cytochrome c (1); PCC, pigeon cytochrome c (1);
HEL, hen egg lysozyme (39); SWMb, sperm whale myoglobin (40);
 rep,   repressor (39); OVA (255–263), chicken ovalbumin (4); Snase,
staphylococcal nuclease (41); LLO, listeriolysin O (42); FluHA, influenza
hemagglutinin (43); HIV, HIV gp120 (44); Mo 2m, mouse  2 micro-
globulin (38); MoCCinh, mouse cytochrome c inhibitor (38); MSA,
mouse serum albumin (38); ER60, mouse ER-60 protease (45).
Figure 3. Details of the p6 and p9 pockets of IEk–pMCC and IEk–
pPCC(T102S). Shown are wire frame representations of residues p6-p10
of pMCC (left) and pPCC(T102S) (right). Also shown for both mole-
cules are side chains of  66Asn,   69Asn,   9Glu,   30Tyr,   37Asn,
 57Asp, and  61Trp. Light yellow, peptide carbon; cyan,   chain car-
bon; magenta,   chain carbon; blue, nitrogen; red, oxygen. Three water
molecules (W1–W3) common to both molecules are shown as well as a
water molecule (W4) that is unique to the IEk–pPCC(T102S) structure
(light blue). Some of the predicted hydrogen bonds among the atoms are
shown as green dotted lines. Figures were made with WebLab ViewerPro
(Accelrys c.).1048 Structures of Cytochrome c Peptides Bound to IEk
nition by various T cell clones (4, 6). These represent all of
the surface-exposed amino acids in the center of the bound
peptides (Fig. 4 A). Of these, the p5Lys has been shown to
be the most important. For most T cell clones raised by im-
munization with pMCC or pPCC, effective stimulation is
critically dependent on a Lys at this position. This Lys is di-
rectly in the center of the binding pocket with its side
chain pointing up and out of the groove into the solvent.
T cell recognition of these peptides is also usually very
dependent on the p8Thr. Substitution of any other amino
acid at this position, even the conserved Thr to Ser substi-
tution shown here, often compromises T cell activation.
For the Thr to Ser change, the peptide is converted to a
weaker agonist in that equivalent T cell activation now re-
quires more peptide (4, 24). For one T cell clone, partial
blocking of the function of CD4 with a monoclonal anti-
body converted this mutant peptide to an antagonist, i.e.,
exposure of the clone to the p8Ser peptide under these
conditions inhibited its response to the wild-type peptide
(54). Another mutation at this position (Thr to Gly) has
also been shown to produce an even more antagonistic
peptide (24).
In the region of p8, the only detectable surface structure
alteration induced by the Thr to Ser substitution was the
loss of the Thr side chain methyl group (Fig. 3 and Fig. 4
A). The C  carbons and hydroxyl oxygens appear to be in
identical positions in both structures. The backbone of the
peptide and the position of the other amino acid side chains
in this region did not change significantly. Therefore, ei-
ther this methyl group is an essential contact point for the
  TCR or, less likely, its loss confers some kinetic instabil-
ity to this region of the molecule that is not revealed by this
static structure. As previously described, the insertion of an
Ala at p9 of pPCC(T102S) has forced the Lys at p10 out of
its binding pocket and onto the molecule surface. This al-
teration does not seem to be detected by most T cell
clones, which suggests that the   TCR does not usually
contact this area of the surface.
The requirements for some of the other solvent-exposed
peptide amino acids are not quite as stringent for recogni-
tion by T cell clones. For example, several receptors accept
an Ala to Gly substitution at p2 or p7, but for the most part
larger amino acids are not tolerated, perhaps because of
steric problems rather than essential receptor–Ala contacts.
Phe, or sometimes Trp but not Leu or Met, is accepted in
place of the p3Tyr, which suggests that an aromatic amino
acid may be essential at this position. In both of our struc-
tures, the close proximity of the Tyr aromatic ring to the
side chain of the p5Lys may indicate a role for this interac-
tion in positioning this crucial Lys for   TCR recogni-
tion. This interaction has been suggested by nuclear mag-
netic resonance studies (55).
IEk Amino Acids Interacting with   TCRs.  A muta-
tional study of IEk revealed a number of amino acids on the
  and   chain   helices that were important for the recog-
nition of the IEk–pMCC complex by T cells (21). In these
experiments, single mutations were introduced into the IEk
molecule at six positions of the   chain ( 53Ser to Asn,
 57Gln to Arg,  61Ala to Val,  64Ala to Val,  68Ala to
Val, and  75Glu to Lys) and seven positions of the   chain
( 59Glu to Lys,  64Gln to Arg,  69Glu to Lys,  73Ala to
Val,  77Thr to Gln,  81His to Tyr, and  84Glu to Lys).
Although no IEk structure was available at the time, the au-
thors predicted that these amino acids would lie on the top
of the   helices based on sequence homology to MHCI
(56). The IEk structures show that this prediction was in-
deed correct (Fig. 4 B).
Each mutated IEk molecule was expressed at the cell sur-
face and tested for binding and presentation of the pMCC
to four different T cell hybridomas. In general, the   chain
mutations had less effect than those on the   chain, al-
though several of the   chain substitutions were quite con-
Figure 4. Surface amino acids of IEk–pMCC and IEk–pPCC(T102S)
that are important for   TCR recognition. (A) A portion of the solvent-
accessible surfaces of the  1 and  1 domains of IEk–pMCC (top) and
IEk–pPCC(T102S) (bottom) are shown. Cyan,   chain; magenta,  
chain. A van der Waal’s Corey, Pauling, Koltan (CPK) representation of
the peptide is shown from p1 to p10. The peptide atoms are white except
for the side chains of the five central surface exposed amino acids and the
Lys at p10 of pPCC(T102S). These are colored by atom type. Yellow,
carbon; blue, nitrogen; red, oxygen. The methyl group of the p8Thr of
pMCC and its absence on the p8Ser of pPCC(T102S) are indicated with
white arrows. The figure was made with WebLab ViewerPro. (B) The
solvent-accessible surfaces of the  1 and  1 domains of IEk–pMCC are
shown. A van der Waal’s CPK representation of the peptide is shown
from p1 to p10 in white. Except for the 13 amino acids mutated in the
study by Jorgensen et al. (20), the IEk   chain is colored cyan and the  
chain is colored magenta. The other 13 amino acids are colored according
to the effects of their mutation. Red, the response of at least three out of
four T cell hybridomas compromised by mutation; orange, the response
of only one out of four T cell hybridomas compromised by mutation;
green, the response of one hybridoma improved by mutation; yellow, no
effect of mutation. The figure was made with WebLab ViewerPro.1049 Fremont et al.
servative (Ala to Val). These amino acids are colored on the
surface of the IEk molecule (Fig. 4 B) according to the ef-
fect of these mutations. Several of the mutations ( 64Gln
to Arg,  69Glu to Lys, and  77Thr to Gln) severely re-
duced the response of at least three of the hybridomas (red).
Others ( 61Ala to Val,  68Ala to Val, and  73Ala to Val)
compromised the response of only one of the four hy-
bridomas (orange). Mutation of  81His to Tyr (green) had
no effect on three of the hybridomas, but greatly enhanced
the response of the fourth. Mutations at the other positions,
which were mainly at the extremities of the   helices, had
no effect on T cell recognition (yellow). In total, these data
suggest that the main sites of   TCR interaction with this
MHCII peptide ligand are clustered on the upward face of
the complex and focused on central peptide residues and
the tops of the arched   helices.
Predicted    TCR Interactions with pMCC and pPCC.
Several studies have investigated   TCR amino acids im-
portant in IEk–pMCC and IEk–pPCC recognition. For ex-
ample, experiments have been performed using pMCC and
variants at position p5 and p8 to immunize mice bearing a
transgene encoding either the   or   chain of an   TCR
from an IEk/pMCC–reactive T cell (20). Thus, the re-
sponding T cells had one of the   TCR chains fixed by
the transgene, whereas the other was allowed to vary.
From the sequences of the CDR3s of the varying   TCR
chain, the authors argued convincingly that the p5Lys in-
teracted with a conserved Glu at position 94 of V CDR3,
whereas the p8Thr interacted with a conserved Asn at posi-
tion 97 of V CDR3.
These two alleles of V 3 have been identified in mice:
V 3a and V 3b (BV3S1A1 and BV3S1A2, respectively).
These differ only at amino acid 31 in what is predicted to
be the V 3 CDR1. This amino acid is Val in V 3a and
Phe in V 3b. V 3 dominates the response to pPCC or
pMCC in mouse strains that carry V 3a, but not in those
with V 3b (57). Furthermore, direct mutation of amino
acid 31 from Val to Phe in the receptor of a V 3a bearing
IEk/pMCC–reactive T cell hybridoma eliminated IEk/
pMCC recognition (10). These findings suggest a critical
interaction between the V 3 CDR1 loop and the IEk–
pMCC and IEk–pPCC ligand, which is disrupted by the
Val to Phe substitution.
There are no crystal structures of   TCRs bound to IEk
peptide. However, it is reasonable to hypothesize that the
orientation of an   TCR bound to IEk will be similar to
those seen in crystal structures of other   TCR complexes
with MHCI and MHCII ligands (58–63). In these struc-
tures, the   TCR sits diagonally on the top of the MHC
molecule, wedged between the arches of the MHC   heli-
ces with the V , and V  CDR3s are centered over the
middle of the peptide. So far, in all cases the orientation of
the    TCR has been similar with V  on the peptide
NH2-terminal side and the V  on the peptide COOH-ter-
minal side. Within these constraints, however, the various
  TCRs swivel by up to 35 .
Therefore, in order to interpret some of these findings
we superimposed IEk–pMCC on the MHCII portion of
two solved   TCR–MHCII peptide complexes (61, 62)
to predict how the CDRs of an anti–IEk/pMCC   TCR
might sit on the ligand (Fig. 5 A and B). These models
strongly support the results of the mutational studies. The
V  and V  CDR3 loops (cyan) are predicted to lie di-
rectly over the center of the pMCC peptide. The side
chain of p5Lys is in close proximity to the predicted posi-
tions of the V 94, and the side chain of p8Thr is in close
proximity to the predicted positions of the V 97. It is easy
to see how mutations in either one of these peptide amino
acids might alter the   TCR binding kinetics and affinity.
The predicted position of V 31 in V  CDR1 is such that
a substitution of Phe for Val at this position would proba-
bly interfere with the interaction of V CDR1 with the  
helix of the IEk   chain. The seven amino acids of IEk that
affect   TCR interaction when mutated all lie in posi-
tions close to the   TCR CDR loops. Overall, this
model agrees remarkably with the published biochemical
and mutational studies.
Figure 5. Predicted T cell receptor interactions with IEk/pMCC. (A)
Top view of the solvent-accessible surface of the  1 and  1 domains of
IEk–pMCC are colored white except for  61,  68,  64,  69,  73,  77,
and  81, which are colored as in Fig. 4 B. A van der Waal’s CPK repre-
sentation of the peptide is shown from p1 to p10 and is colored as in Fig.
4 A. Two   TCRs, one from HA1.7 (specific for DR1 plus a peptide
from influenza hemagglutinin) (64) and the second from D10 (specific for
IAk plus a peptide from conalbumin) (65), whose structures were solved
bound to their MHCII peptide ligands (61, 62), were aligned on the
IEk–pMCC structure by superimposing the backbones of the MHC mol-
ecule  1 and  1 domains. Ribbons, the V  and V  CDR loops ( 1,  2,
 3,  1,  2, and  3) of the two   TCRs; dark green, HA1.7   TCR
V /  CDR1; purple, V /  CDR2; blue, V /  CDR3; light green,
D10    TCR V /  CDR1; magenta, V /  CDR2; cyan, V / 
CDR3. The positions of three   TCR amino acids, V 94, V 31, and
V 97, are labeled and colored red. (B) Side view of the peptide and
CDR3 portions of Fig. 4 A with other parts of the molecules removed.
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